The US Food and Drug Administration (FDA) has cleared NM-101 (Terran Biosciences), a cloud-based software platform to analyze neuromelanin-sensitive MRI scans, which could aid in the diagnosis of neurodegenerative diseases. Research has suggested that neuromelanin is a potential biomarker for neurologic disorders such as Parkinson’s disease (PD). A recent meta-analysis of 12 neuromelanin MRI studies...